140 related articles for article (PubMed ID: 34936121)
1. Bamlanivimab plus etesevimab treatment have a better outcome against COVID-19: A meta-analysis.
Xiang HR; He B; Li Y; Cheng X; Zhang QZ; Peng WX
J Med Virol; 2022 May; 94(5):1893-1905. PubMed ID: 34936121
[TBL] [Abstract][Full Text] [Related]
2. Effect of Bamlanivimab as Monotherapy or in Combination With Etesevimab on Viral Load in Patients With Mild to Moderate COVID-19: A Randomized Clinical Trial.
Gottlieb RL; Nirula A; Chen P; Boscia J; Heller B; Morris J; Huhn G; Cardona J; Mocherla B; Stosor V; Shawa I; Kumar P; Adams AC; Van Naarden J; Custer KL; Durante M; Oakley G; Schade AE; Holzer TR; Ebert PJ; Higgs RE; Kallewaard NL; Sabo J; Patel DR; Klekotka P; Shen L; Skovronsky DM
JAMA; 2021 Feb; 325(7):632-644. PubMed ID: 33475701
[TBL] [Abstract][Full Text] [Related]
3. SARS-CoV-2-neutralising monoclonal antibodies for treatment of COVID-19.
Kreuzberger N; Hirsch C; Chai KL; Tomlinson E; Khosravi Z; Popp M; Neidhardt M; Piechotta V; Salomon S; Valk SJ; Monsef I; Schmaderer C; Wood EM; So-Osman C; Roberts DJ; McQuilten Z; Estcourt LJ; Skoetz N
Cochrane Database Syst Rev; 2021 Sep; 9(9):CD013825. PubMed ID: 34473343
[TBL] [Abstract][Full Text] [Related]
4. Effects of bamlanivimab alone or in combination with etesevimab on subsequent hospitalization and mortality in outpatients with COVID-19: a systematic review and meta-analysis.
Tai YL; Lee MD; Chi H; Chiu NC; Lei WT; Weng SL; Liu LY; Chen CC; Huang SY; Huang YN; Lin CY
PeerJ; 2023; 11():e15344. PubMed ID: 37180576
[TBL] [Abstract][Full Text] [Related]
5. Clinical efficacy of different monoclonal antibody regimens among non-hospitalised patients with mild to moderate COVID-19 at high risk for disease progression: a prospective cohort study.
Savoldi A; Morra M; De Nardo P; Cattelan AM; Mirandola M; Manfrin V; Scotton P; Giordani MT; Brollo L; Panese S; Lanzafame M; Scroccaro G; Berkell M; Lippi G; Konnova A; Smet M; Malhotra-Kumar S; Kumar-Singh S; Tacconelli E;
Eur J Clin Microbiol Infect Dis; 2022 Jul; 41(7):1065-1076. PubMed ID: 35727429
[TBL] [Abstract][Full Text] [Related]
6. Bamlanivimab plus Etesevimab in Mild or Moderate Covid-19.
Dougan M; Nirula A; Azizad M; Mocherla B; Gottlieb RL; Chen P; Hebert C; Perry R; Boscia J; Heller B; Morris J; Crystal C; Igbinadolor A; Huhn G; Cardona J; Shawa I; Kumar P; Adams AC; Van Naarden J; Custer KL; Durante M; Oakley G; Schade AE; Holzer TR; Ebert PJ; Higgs RE; Kallewaard NL; Sabo J; Patel DR; Dabora MC; Klekotka P; Shen L; Skovronsky DM;
N Engl J Med; 2021 Oct; 385(15):1382-1392. PubMed ID: 34260849
[TBL] [Abstract][Full Text] [Related]
7. Curbing the Delta Surge: Clinical Outcomes After Treatment With Bamlanivimab-Etesevimab, Casirivimab-Imdevimab, or Sotrovimab for Mild to Moderate Coronavirus Disease 2019.
Razonable RR; O'Horo JC; Challener DW; Arndt L; Arndt RF; Clune CG; Culbertson TL; Hall ST; Heyliger A; Jackson TA; Kennedy BD; Larsen J; Hanson SN; Sweeten PW; Tulledge-Scheitel SM; Ganesh R
Mayo Clin Proc; 2022 Sep; 97(9):1641-1648. PubMed ID: 36058578
[TBL] [Abstract][Full Text] [Related]
8. Endogenous Antibody Responses to SARS-CoV-2 in Patients With Mild or Moderate COVID-19 Who Received Bamlanivimab Alone or Bamlanivimab and Etesevimab Together.
Zhang L; Poorbaugh J; Dougan M; Chen P; Gottlieb RL; Huhn G; Beasley S; Daniels M; Ngoc Vy Trinh T; Crisp M; Freitas JJ; Vaillancourt P; Patel DR; Nirula A; Kallewaard NL; Higgs RE; Benschop RJ
Front Immunol; 2021; 12():790469. PubMed ID: 34956222
[TBL] [Abstract][Full Text] [Related]
9. A Randomized, Placebo-Controlled Clinical Trial of Bamlanivimab and Etesevimab Together in High-Risk Ambulatory Patients With COVID-19 and Validation of the Prognostic Value of Persistently High Viral Load.
Dougan M; Azizad M; Mocherla B; Gottlieb RL; Chen P; Hebert C; Perry R; Boscia J; Heller B; Morris J; Crystal C; Igbinadolor A; Huhn G; Cardona J; Shawa I; Kumar P; Blomkalns A; Adams AC; Van Naarden J; Custer KL; Knorr J; Oakley G; Schade AE; Holzer TR; Ebert PJ; Higgs RE; Sabo J; Patel DR; Dabora MC; Williams M; Klekotka P; Shen L; Skovronsky DM; Nirula A
Clin Infect Dis; 2022 Aug; 75(1):e440-e449. PubMed ID: 34718468
[TBL] [Abstract][Full Text] [Related]
10. SARS-CoV-2 neutralizing antibodies for COVID-19: Outcomes for bamlanivimab versus bamlanivimab-etesevimab combination in a racially diverse cohort of patients with significant comorbidities.
Monday LM; Brar I; Alangaden G; Ramesh MS
J Clin Pharm Ther; 2022 Sep; 47(9):1438-1443. PubMed ID: 35633095
[TBL] [Abstract][Full Text] [Related]
11. PK/PD modeling links accelerated resolution of COVID-19-related clinical symptoms to SARS-CoV-2 viral load reduction in patients following treatment with Bamlanivimab alone or Bamlanivimab and Etesevimab together.
Ernest CS; Chien JY; Patel DR; Chigutsa E
CPT Pharmacometrics Syst Pharmacol; 2022 Jun; 11(6):721-730. PubMed ID: 35289125
[TBL] [Abstract][Full Text] [Related]
12. Do we need bamlanivimab? Is etesevimab a key to treating Covid-19?
Doggrell SA
Expert Opin Biol Ther; 2021 Nov; 21(11):1359-1362. PubMed ID: 34555986
[TBL] [Abstract][Full Text] [Related]
13. SARS-CoV-2 Spike Protein-Directed Monoclonal Antibodies May Ameliorate COVID-19 Complications in APECED Patients.
Ferré EMN; Schmitt MM; Ochoa S; Rosen LB; Shaw ER; Burbelo PD; Stoddard JL; Rampertaap S; DiMaggio T; Bergerson JRE; Rosenzweig SD; Notarangelo LD; Holland SM; Lionakis MS
Front Immunol; 2021; 12():720205. PubMed ID: 34504497
[TBL] [Abstract][Full Text] [Related]
14. Atrial fibrillation with aberrant ventricular conduction after receiving Bamlanivimab/Etesevimab: a case report.
Palazzo AG; Zizza A; Nuzzo M; Urciuoli C; Scardia S; Romano A; Guido M; Grima P
Curr Med Res Opin; 2022 Jul; 38(7):1055-1057. PubMed ID: 35608093
[TBL] [Abstract][Full Text] [Related]
15. Rates of Severe Outcomes After Bamlanivimab-Etesevimab and Casirivimab-Imdevimab Treatment of High-Risk Patients With Mild to Moderate Coronavirus Disease 2019.
O'Horo J; Challener DW; Anderson RJ; Arndt RF; Ausman SE; Hall ST; Heyliger A; Kennedy BD; Sweeten PW; Ganesh R; Razonable RR
Mayo Clin Proc; 2022 May; 97(5):943-950. PubMed ID: 35512884
[TBL] [Abstract][Full Text] [Related]
16. The comparative effectiveness of COVID-19 monoclonal antibodies: A learning health system randomized clinical trial.
McCreary EK; Bariola JR; Minnier TE; Wadas RJ; Shovel JA; Albin D; Marroquin OC; Kip KE; Collins K; Schmidhofer M; Wisniewski MK; Nace DA; Sullivan C; Axe M; Meyers R; Weissman A; Garrard W; Peck-Palmer OM; Wells A; Bart RD; Yang A; Berry LR; Berry S; Crawford AM; McGlothlin A; Khadem T; Linstrum K; Montgomery SK; Ricketts D; Kennedy JN; Pidro CJ; Haidar G; Snyder GM; McVerry BJ; Yealy DM; Angus DC; Nakayama A; Zapf RL; Kip PL; Seymour CW; Huang DT
Contemp Clin Trials; 2022 Aug; 119():106822. PubMed ID: 35697146
[TBL] [Abstract][Full Text] [Related]
17. Efficacy and safety of bamlanivimab in patients with COVID-19: A systematic review and meta-analysis.
Amani B; Khodavirdilou L; Rajabkhah K; Kardan Moghaddam V; Akbarzadeh A; Amani B
World J Virol; 2024 Mar; 13(1):88660. PubMed ID: 38616851
[TBL] [Abstract][Full Text] [Related]
18. Exploratory data on the clinical efficacy of monoclonal antibodies against SARS-CoV-2 Omicron variant of concern.
Mazzaferri F; Mirandola M; Savoldi A; De Nardo P; Morra M; Tebon M; Armellini M; De Luca G; Calandrino L; Sasset L; D'Elia D; Sozio E; Danese E; Gibellini D; Monne I; Scroccaro G; Magrini N; Cattelan A; Tascini C; ; Tacconelli E
Elife; 2022 Nov; 11():. PubMed ID: 36413383
[TBL] [Abstract][Full Text] [Related]
19. Bamlanivimab Reduces ED Returns and Hospitalizations and May Reduce COVID-19 Burden on Low-resource Border Hospitals.
Quenzer FC; Lafree AT; Grey L; Singh S; Smyers C; Balog B; Guedez HM; McIntyre K; Wulfovich S; Ramirez J; Saikhon T; Tomaszewski C
West J Emerg Med; 2022 Mar; 23(3):302-311. PubMed ID: 35679495
[TBL] [Abstract][Full Text] [Related]
20. Intravenous bamlanivimab use associates with reduced hospitalization in high-risk patients with mild to moderate COVID-19.
Ganesh R; Pawlowski CF; O'Horo JC; Arndt LL; Arndt RF; Bell SJ; Bierle DM; Borgen MD; Hanson SN; Heyliger A; Larsen JJ; Lenehan PJ; Orenstein R; Puranik A; Speicher LL; Tulledge-Scheitel SM; Venkatakrishnan AJ; Wilker CG; Badley AD; Razonable RR
J Clin Invest; 2021 Oct; 131(19):. PubMed ID: 34411003
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
